Phase I and Pharmacokinetics Study to Determine the Safety of CHS 828 in Patients With a Solid Tumor on a Single Oral Dose Repeated Every 3 Weeks.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2013
At a glance
- Drugs CHS 828 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jul 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.